The topic knowledgeable panel on vaccines has really helpful the drug regulator to grant emergency use authorization (EUA) to Russia’s Sputnik Light single-dose vaccine, sources mentioned on Friday.
Sputnik Light is developed by Russia’s Gamalea Center, constructed on a human adenovirus vector platform. In October final 12 months, the federal government had accredited the export of Sputnik Light, manufactured in India by Hetero Biopharma Limited.
The Sputnik is similar as component-1 of the Russian Sputnik V vaccine that has been utilized in India’s vaccination drive. India has administered near 12 lakh doses of Sputnik V in the course of the grownup vaccination drive.
The firm had earlier mentioned that the single-shot vaccine has demonstrated 70 per cent efficacy towards an infection by the Delta variant.
“A preliminary study of the Gamalea Center has found Sputnik Light significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination with 100% of individuals revaccinated with Sputnik Light as a booster having developed neutralizing antibodies against this variant,” the Russian Direct Investment Fund had mentioned earlier.
,
With inputs from TheIndianEXPRESS
